A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Inclusion Criteria: * Subject is treated by maximum medical management（ pharmacological therapy and nonpharmacological therapy ) for 3 months and over before screening testing and the same treatment will be conducted during the study period. * Subject must have severe dyspnea which is defined as a mMRC ≥ 2. * Subject's obstructive disease is severe as defined by following post-bronchodilator spirometry values: FEV1/FVC \< 70% and 20% of predicted ≤ FEV1 \< 50% of predicted * Subject's hyperinflation is defined by: RV/TLC ≥ 40% * Subject has severe emphysema and high heterogeneity defined as: a target lobe with ≥ 50% emphysema involvement and clearly different with the ipsilateral lobe, which is judged by visual assessment of thoracic CT. Lung perfusion scan is added to the assessment in principle. * The target lobe and ipsilateral lobe will be separated with an intact fissure. An intact fissure will be estimated visually to be ≥ 90% complete with no segmental vessels crossing from one lobe to the adjacent lobe. * Subject must be able to demonstrate physical ability to participate in the study by performing a 6-minute walk distance of ≥ 140 m. * Subject has abstained from cigarette smoking for 3 months and over before screening testing, and is able to continue to abstain throughout the study. * Investigator has confirmed that medical management has been conducted enough and disease state has been stable and without a COPD exacerbation for 6 weeks and over before screening testing. * Subject is able to participate in the study, complete the required follow-up visits, and maintain consistent nutrition and exercise habits during the study period. * Subject provides informed consent and is willing and able to return for all study examinations. Exclusion Criteria: * Subject has a severe gas exchange abnormality in either PaCO2 or PaO2 as defined by: PCO2 \> 50 mmHg, or PO2 \< 50 mmHg on room air * Subject with DLCO \< 20% of predicted * Subject has a BMI \< 15kg/m2. * Subject has a risk of thromboembolism.(D-dimer value is used as a reference.) * Subject had COPD exacerbation which required hospitalization or administration of systemic steroids twice or more in the past 1 year prior to screening testing. * Subject has a history of pneumothorax twice or more in the past 1 year prior to screening testing. * Subject has a large amount of sputum production on a daily basis. * Subject has clinically apparent asthma. * Subject has giant bulla (\> 1/3 volume in either lung. If subject has multiple bullae, the sum of them is judged whether or not \> 1/3 volume in either lung. ) * Patient has pulmonary hypertension based upon clinical evaluation. * Subject uses oral steroids 10 mg/day and over in prednisolone conversion. * Subject has comorbidities that will limit participation in the study, or follow-up during the study period. * Subject has a history of thoracic surgeries. * Subject has thoracic comorbidities (lung nodules, infections(e.g. Pulmonary tuberculosis), Interstitial pneumonia, etc.) , which are anticipated to require evaluation or intervention during the 12 months study period. * Subject is strongly suspected of pleural adhesions. * Subject has indicated Left ventricular ejection fraction(LVEF) ≤ 30% within 6 months prior to screening testing. \*Subject,who had severe cardiovascular diseases in the past but can control them currently, doesn't meet this criteria. * Subject is judged as ineligible due to a risk of hemoptysis by investigators. * Subject has demonstrated unwillingness or inability to complete screening and/or baseline testing. * Subject has α1-antitrypsin deficiency. * Subject is classified as ASA Class greater than P4 or has comorbidities that could significantly increase the risk related with bronchoscopy procedure. * Subject has latex allergy. * Subject has metallic allergy. * Subject participated in a study of an investigational drug or device within the 30 days prior to participation in this study, or is currently participating in another clinical study. * Following women subjects are ineligible: Pregnant women, lactating women, potentially pregnant women, women who wish to become pregnant during the study period, women who cannot use birth control properly during the study period. * Subject is considered as ineligible due to other factors by investigators.